Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Tanespimycin (17-AAG) Chemical Structure

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Size Price Stock Quantity  
In DMSO USD 195 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • (A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

    PNAS, 2011, 108: 7535-40. Tanespimycin (17-AAG) purchased from Selleck.

    (A) Treatment of DIPG cells with an HSP90 inhibitor, 17-AAG, resulted in decreased invasion toward SVZ hNPC CM at high doses. (B) Cell viability of DIPG cells treated with increasing doses of 17-AAG, by the CellTiter-Glo assay.

    Cell, 2017, 170(5):845-859.e19. Tanespimycin (17-AAG) purchased from Selleck.

  • SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

    Mol Cancer 2014 13, 150. Tanespimycin (17-AAG) purchased from Selleck.

    Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

    Oncotarget, 2015, 51: S659-S660. Tanespimycin (17-AAG) purchased from Selleck.

  • Co-IP analyses of direct interaction between HSP90 and HIF-1α in 17-AAG (5 μM)-treated HSCs using antibodies against HSP90, HIF-1α or IgG (n = 2).

    Br J Pharmacol, 2017, 174(5):409-423. Tanespimycin (17-AAG) purchased from Selleck.

    Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

    J Biol Chem 2012 287, 44109-20. Tanespimycin (17-AAG) purchased from Selleck.

  • UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

    Mol Cell Biol 2013 33(12), 2375-87. Tanespimycin (17-AAG) purchased from Selleck.

    Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

    Age 2013 35, 549-62. Tanespimycin (17-AAG) purchased from Selleck.

  • Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

    Oncotarget 2014 5, 4269-82. Tanespimycin (17-AAG) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.
Features Displays very low toxicity toward normal cells.
Targets
HSP90 [1]
(Cell-free assay)
5 nM
In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. [1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. [2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\xUZk5UUN3ME2wMlAxODNyMzFOwG0> M2rqXnNCVkeHUh?=
IST-MEL1 NWDhbJRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLtTWM2OD1yLkCwNFQxPyEQvF2= M4jLcHNCVkeHUh?=
NCI-SNU-1 NIi0XpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7xRmlQUUN3ME2wMlAxOjB5IN88US=> M2e2NXNCVkeHUh?=
FADU MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITlOpJKSzVyPUCuNFAzODlizszN MXnTRW5ITVJ?
C32 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX0cYJ4UUN3ME2wMlAxOzB2IN88US=> MXjTRW5ITVJ?
D-566MG Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHHd5pqUUN3ME2wMlAxOzlizszN MonzV2FPT0WU
LXF-289 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG2TWM2OD1yLkCwOFE6KM7:TR?= MX\TRW5ITVJ?
HGC-27 Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDF[Ik6UUN3ME2wMlAxPTFizszN MmLGV2FPT0WU
RPMI-7951 Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX3RmtpUUN3ME2wMlAxPzF5IN88US=> NVnY[IFJW0GQR1XS
HSC-3 NHjEW5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TPSGlEPTB;MD6wNFkzQSEQvF2= MlPVV2FPT0WU
MIA-PaCa-2 M3;mXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLHTWM2OD1yLkCxNFA6KM7:TR?= NGX5SVhUSU6JRWK=
KS-1 NWjhZ2dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW0TWM2OD1yLkCxN|U2KM7:TR?= MnPEV2FPT0WU
CAL-51 M3rhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG2dotKSzVyPUCuNFE1ODVizszN MU\TRW5ITVJ?
MDA-MB-361 MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMEG0PVUh|ryP NX;6bItbW0GQR1XS
TI-73 NIDIZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHiPJJnUUN3ME2wMlAyPzl4IN88US=> M3WzSHNCVkeHUh?=
AGS NWqwWZR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzpTWM2OD1yLkCxPVM5KM7:TR?= Ml7GV2FPT0WU
NCI-H460 NES5TW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K4[WlEPTB;MD6wNVk4PCEQvF2= MnjRV2FPT0WU
A204 M1LadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMEKyOFkh|ryP NFfPeHZUSU6JRWK=
CHL-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXPWXBKSzVyPUCuNFIzPTFizszN NYe2T2Z3W0GQR1XS
DU-4475 M4\Ib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7wfpdKSzVyPUCuNFIzPjFizszN NVfwOWtEW0GQR1XS
CGTH-W-1 MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMEKzOFkh|ryP NHTnNHJUSU6JRWK=
HCC2218 NEW1fWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkW1TWM2OD1yLkCyOFk1KM7:TR?= MYXTRW5ITVJ?
A2780 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XBZ2lEPTB;MD6wNlU{OSEQvF2= NVL6bnpGW0GQR1XS
NCI-H720 MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\mTGlEPTB;MD6wNlU1PiEQvF2= M3L0PXNCVkeHUh?=
NCI-N87 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLQTWM2OD1yLkCyOVk{KM7:TR?= M2jBSHNCVkeHUh?=
CHP-212 NU[4R5RvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17Zd2lEPTB;MD6wNlYzQCEQvF2= NGLGWYRUSU6JRWK=
NCI-H23 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\zbWlEPTB;MD6wNlY3PSEQvF2= MYHTRW5ITVJ?
D-263MG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnkZllKSzVyPUCuNFI4QDZizszN NWnlNYdzW0GQR1XS
ME-180 MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTzcpJSUUN3ME2wMlAzQDlzIN88US=> Mmr3V2FPT0WU
SW982 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XXXGlEPTB;MD6wNlk6QSEQvF2= NUfL[mU6W0GQR1XS
OE19 MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vDeGlEPTB;MD6wN|A4PyEQvF2= MkC2V2FPT0WU
SK-LU-1 MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnzRZJwUUN3ME2wMlA{ODh{IN88US=> NH;jTmhUSU6JRWK=
H4 M1;jNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMEOwPUDPxE1? Ml36V2FPT0WU
HT-144 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\tTWM2OD1yLkCzNFk{KM7:TR?= M3nzd3NCVkeHUh?=
SK-UT-1 NULnT|NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7rSZRKSzVyPUCuNFMyPzhizszN NIfUXGVUSU6JRWK=
D-336MG NY\C[mRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7lNo1KSzVyPUCuNFM{ODlizszN MUnTRW5ITVJ?
MDA-MB-175-VII MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH31OnpKSzVyPUCuNFM{PTRizszN NGPsbHBUSU6JRWK=
GAMG NYDXXIt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMEO0N|Uh|ryP NHu3WIZUSU6JRWK=
CP50-MEL-B M4jK[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMEO0OUDPxE1? MW\TRW5ITVJ?
OVCAR-5 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml25TWM2OD1yLkCzOFgh|ryP NWC1NW1nW0GQR1XS
SK-MES-1 M1GzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7RWWZKUUN3ME2wMlA{PjB4IN88US=> NIH4VGVUSU6JRWK=
VM-CUB-1 NFTD[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMEO2OVch|ryP NVTpOHRpW0GQR1XS
WM-115 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMEO3OlIh|ryP NV:0VIZ6W0GQR1XS
DSH1 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMEO4NFch|ryP MYXTRW5ITVJ?
Becker NH;HcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvKTWM2OD1yLkCzPFg2KM7:TR?= NY\U[2dqW0GQR1XS
SW962 NUPTPFAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zKRmlEPTB;MD6wN|k1PSEQvF2= M4\EeXNCVkeHUh?=
TYK-nu M{[ydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrsZ|I2UUN3ME2wMlA{QTh3IN88US=> MnvNV2FPT0WU
HO-1-N-1 MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPKZmFPUUN3ME2wMlA1ODJzIN88US=> M3z3WXNCVkeHUh?=
T98G MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\PfGlEPTB;MD6wOFExOyEQvF2= MlTSV2FPT0WU
ACN M37mTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fVdWlEPTB;MD6wOFE3OiEQvF2= MVLTRW5ITVJ?
SW780 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrPTWM2OD1yLkC0NlA{KM7:TR?= MUDTRW5ITVJ?
Detroit562 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrOTWM2OD1yLkC0NlM6KM7:TR?= MWXTRW5ITVJ?
BB49-HNC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33yOWlEPTB;MD6wOFI1OyEQvF2= Mmq5V2FPT0WU
HN NWfGdJBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3izfmlEPTB;MD6wOFI4OiEQvF2= MlnlV2FPT0WU
H9 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfjS3l[UUN3ME2wMlA1OzdzIN88US=> M3PXdXNCVkeHUh?=
VA-ES-BJ NIHOOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P2bWlEPTB;MD6wOFQ1PyEQvF2= M2fLXHNCVkeHUh?=
MEL-JUSO M3zRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULiTVhJUUN3ME2wMlA1PDd3IN88US=> NGDk[FVUSU6JRWK=
BT-474 M2\kfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3oTWM2OD1yLkC0OUDPxE1? NHjPT3ZUSU6JRWK=
CaR-1 M13L[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DRcWlEPTB;MD6wOFU1QSEQvF2= NFe5c5RUSU6JRWK=
PSN1 NI\nSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInIb3NKSzVyPUCuNFQ3ODNizszN NGrtV2xUSU6JRWK=
KYSE-510 NUjoZWNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\hZllKSzVyPUCuNFQ3PDlizszN NVvsUoVtW0GQR1XS
KP-4 NWXSXXhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\rbm97UUN3ME2wMlA1PzV|IN88US=> NVzZOI9[W0GQR1XS
KYSE-410 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH6TWM2OD1yLkC0O|czKM7:TR?= M{nld3NCVkeHUh?=
G-402 NV3ScIJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfUTWM2OD1yLkC0O|g6KM7:TR?= M4[2VXNCVkeHUh?=
DOK M37o[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr4TWM2OD1yLkC0PVAzKM7:TR?= NWPhZYptW0GQR1XS
COR-L88 NUHQXGtLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMES5NVIh|ryP NXH6b2hZW0GQR1XS
SKG-IIIa NWLIXlI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMES5PFYh|ryP M{XDfHNCVkeHUh?=
AN3-CA M17PO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\0TWM2OD1yLkC1JO69VQ>? NEeyNoVUSU6JRWK=
SW48 MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXqXVV5UUN3ME2wMlA2ODN7IN88US=> MWnTRW5ITVJ?
YKG-1 MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMEWwO|Eh|ryP NW\rNmJNW0GQR1XS
KYSE-150 NYnGS2lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvFPJNpUUN3ME2wMlA2OjN3IN88US=> MoCyV2FPT0WU
HuO-3N1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\wVnhKSzVyPUCuNFUzOzdizszN NGjFd2xUSU6JRWK=
LB1047-RCC MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjz[2NKSzVyPUCuNFUzQTZizszN NWf5bIVHW0GQR1XS
NCI-H2030 NVm5TI9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMEW0NVQh|ryP M2jLUXNCVkeHUh?=
YH-13 NFP4[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{eyNmlEPTB;MD6wOVczOiEQvF2= MXHTRW5ITVJ?
5637 MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMEW3OEDPxE1? NVzOepI3W0GQR1XS
LOXIMVI Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4THbmlEPTB;MD6wOVg4OiEQvF2= M{jHTnNCVkeHUh?=
GT3TKB MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrGe5ZKSzVyPUCuNFU6PDJizszN NXfNe|FEW0GQR1XS
TCCSUP NF3INIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXNd3ROUUN3ME2wMlA2QTZ2IN88US=> Mo[5V2FPT0WU
EPLC-272H NUPucYFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLNcGpXUUN3ME2wMlA3OjB3IN88US=> NWexdmdEW0GQR1XS
LU-99A NWCwfHB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;rTmlEPTB;MD6wOlI{PyEQvF2= MofFV2FPT0WU
NCI-H1755 NUTifmIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwME[zOFEh|ryP M3XwZ3NCVkeHUh?=
KM12 Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwME[zOFgh|ryP NIHxW3NUSU6JRWK=
SF295 MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDGR2pMUUN3ME2wMlA3PDV{IN88US=> MorlV2FPT0WU
MZ2-MEL NIT0WXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwME[1OVMh|ryP NIHMeZlUSU6JRWK=
HEC-1 M2\ZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO0bm9MUUN3ME2wMlA3PTh6IN88US=> M1n6RnNCVkeHUh?=
SW684 M1HkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\pTWM2OD1yLkC2OVkyKM7:TR?= M{nWfHNCVkeHUh?=
SF539 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG4TWM2OD1yLkC2OlgyKM7:TR?= MmXhV2FPT0WU
GMS-10 Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jURmlEPTB;MD6wOlY6QSEQvF2= M3TSSnNCVkeHUh?=
MV-4-11 Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\tcXVlUUN3ME2wMlA3QDB|IN88US=> NGOwSFRUSU6JRWK=
HT-29 Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fxRmlEPTB;MD6wOlkyQSEQvF2= NWq1PGZQW0GQR1XS
23132-87 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3S4R2lEPTB;MD6wOlk2KM7:TR?= NFjY[INUSU6JRWK=
SW620 NHnV[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMEewNlYh|ryP NVHSWmNPW0GQR1XS
HCC1806 M{D2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPpUFg2UUN3ME2wMlA4OTNzIN88US=> M3vQNnNCVkeHUh?=
Hs-578-T MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMEeyNFgh|ryP NV;XfIJCW0GQR1XS
A2058 M2rJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMEeyNlgh|ryP NEj5[GRUSU6JRWK=
MEL-HO M3j1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIO0OVRKSzVyPUCuNFczPTVizszN NXz1OIc3W0GQR1XS
HCC2998 MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnSTWM2OD1yLkC3N|Q4KM7:TR?= M{XS[HNCVkeHUh?=
HuO9 NUT6Nm1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDteoNKSzVyPUCuNFc2QDlizszN MkHpV2FPT0WU
CAL-39 NWi3RoI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorjTWM2OD1yLkC3O|Y3KM7:TR?= MmPUV2FPT0WU
M14 MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF23fHBKSzVyPUCuNFc6OTNizszN MkC2V2FPT0WU
BFTC-909 NXf4eVJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\rN4NGUUN3ME2wMlA4QTZ7IN88US=> M{DmTXNCVkeHUh?=
TE-11 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXPTWM2OD1yLkC3PVk3KM7:TR?= MYfTRW5ITVJ?
TGBC1TKB M1HFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjNdVVKSzVyPUCuNFgxPDNizszN MWnTRW5ITVJ?
L-363 NH7QN5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XKVmlEPTB;MD6wPFIxPiEQvF2= MUDTRW5ITVJ?
A431 MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3yxe2lEPTB;MD6wPFIyKM7:TR?= Mle0V2FPT0WU
MKN45 NFzWdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzLO5hjUUN3ME2wMlA5OjF7IN88US=> MofGV2FPT0WU
HT-1080 NFvReHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPxTWM2OD1yLkC4OFM6KM7:TR?= MUXTRW5ITVJ?
OVCAR-8 NE\XV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\PWGZKSzVyPUCuNFg3OjJizszN MlrLV2FPT0WU
LCLC-97TM1 NXLJUHhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWmyPJptUUN3ME2wMlA5PzJ6IN88US=> M3H4V3NCVkeHUh?=
M059J NHHvXYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXKXWhzUUN3ME2wMlA6ODJ5IN88US=> M2PyTXNCVkeHUh?=
SK-MEL-2 NVXQSY9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMEmwOkDPxE1? M1r5Z3NCVkeHUh?=
TE-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jJbWlEPTB;MD6wPVIxPCEQvF2= M1jHenNCVkeHUh?=
KYSE-180 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrZTWM2OD1yLkC5NlYzKM7:TR?= MnfCV2FPT0WU
D-247MG MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\vc3pKSzVyPUCuNFk1PTVizszN MVvTRW5ITVJ?
8-MG-BA M17SZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPs[WRCUUN3ME2wMlA6PDd{IN88US=> NUDvZVFWW0GQR1XS
NCI-H1792 NH72V25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PsNmlEPTB;MD6wPVYyQCEQvF2= NUX0RYo1W0GQR1XS
MCF7 MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL2R5U4UUN3ME2wMlA6Pjd5IN88US=> NVrCWZlwW0GQR1XS
NCI-H2122 NHPRb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\yb2lEPTB;MD6wPVc1PSEQvF2= M{L0VXNCVkeHUh?=
EFO-27 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LU[WlEPTB;MD6wPVk6PyEQvF2= M{X2fnNCVkeHUh?=
LB2241-RCC M3P3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMUCwOVQh|ryP NHrpS3RUSU6JRWK=
SN12C MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMUCxNFch|ryP NX;DcWNFW0GQR1XS
A498 MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\lTWM2OD1yLkGwNVgh|ryP NEP3[Y9USU6JRWK=
PANC-03-27 M4rJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMUCyPFYh|ryP NFjZUFBUSU6JRWK=
NCI-H1581 M1GwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PpVWlEPTB;MD6xNFI6KM7:TR?= MoLjV2FPT0WU
U-87-MG MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vYfGlEPTB;MD6xNFMxPyEQvF2= MlTMV2FPT0WU
G-401 M13aS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPCUldKSzVyPUCuNVA{PTNizszN M1\WdHNCVkeHUh?=
SiHa M1rueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4myW2lEPTB;MD6xNFQ5PiEQvF2= NGrVUoJUSU6JRWK=
U251 NITYdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMUC1NlUh|ryP Mn3TV2FPT0WU
MMAC-SF MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS3SIlTUUN3ME2wMlExPTNzIN88US=> NEnJUWJUSU6JRWK=
BB65-RCC NIPze4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnNPWFKSzVyPUCuNVA2PTRizszN NHL6ZpVUSU6JRWK=
NKM-1 M1vsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMUC2OlYh|ryP M2rSfXNCVkeHUh?=
HD-MY-Z M2i1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH74V|ZKSzVyPUCuNVA5PzNizszN NXHuWZZ3W0GQR1XS
TGBC11TKB NGnzUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nJWGlEPTB;MD6xNFkxOyEQvF2= MlrzV2FPT0WU
COLO-679 Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMUGyNVEh|ryP MmPtV2FPT0WU
TE-8 M1zuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzDc4NXUUN3ME2wMlEyOjZ2IN88US=> NEDTUoVUSU6JRWK=
SK-MEL-28 MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFO5S41KSzVyPUCuNVE{OjFizszN M2DLRXNCVkeHUh?=
SH-4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fP[WlEPTB;MD6xNVM2PiEQvF2= NWfCXGN{W0GQR1XS
KALS-1 Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMUGzPVMh|ryP MV;TRW5ITVJ?
RKO MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTZNVNNUUN3ME2wMlEyPzZ2IN88US=> NXvQbZplW0GQR1XS
OMC-1 M3u4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwMUG3PVch|ryP Mm\ZV2FPT0WU
BT-549 NYq2[mFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnZTWM2OD1yLkGxO|k6KM7:TR?= MVTTRW5ITVJ?
NCI-H28 NYrYZYhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\STWM2OD1yLkGxPFE4KM7:TR?= MmHRV2FPT0WU
RXF393 M3TYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMUG5PFIh|ryP M4Xj[XNCVkeHUh?=
COLO-829 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMUKwNFUh|ryP NWrEfnB6W0GQR1XS
HMV-II MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfETWM2OD1yLkGyNFIh|ryP MXvTRW5ITVJ?
SW1990 NGG2OIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMUKxOVch|ryP NGnmUINUSU6JRWK=
NCI-H1437 Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnwTWM2OD1yLkGyNVU4KM7:TR?= M1H2d3NCVkeHUh?=
SNB75 M3jWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMUKxOlkh|ryP MXLTRW5ITVJ?
EW-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr1dnhKSzVyPUCuNVI3PjFizszN NEHpfoJUSU6JRWK=
SAS NXvKTlhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\y[GlEPTB;MD6xNlY6KM7:TR?= NVzVTmZ3W0GQR1XS
NCI-H1666 MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PCUGlEPTB;MD6xNlc4PCEQvF2= M4XEVHNCVkeHUh?=
A375 MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;NfWlEPTB;MD6xNlc4QCEQvF2= MXnTRW5ITVJ?
CAMA-1 Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:xTWM2OD1yLkGyPVI1KM7:TR?= MWHTRW5ITVJ?
HuP-T4 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{freGlEPTB;MD6xNlk1OyEQvF2= MWfTRW5ITVJ?
NCI-H292 M1vlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmKzTWM2OD1yLkGzNVEh|ryP NUGzWWZuW0GQR1XS
PC-14 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXBSoxKSzVyPUCuNVMzOTFizszN NX7LNogxW0GQR1XS
BPH-1 NETOUlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;aTWM2OD1yLkGzOFEh|ryP MoPNV2FPT0WU
GAK MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMUO1Olch|ryP Ml\zV2FPT0WU
VMRC-RCZ NE\ZO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPPOIdHUUN3ME2wMlE{PzZ{IN88US=> NH60e|ZUSU6JRWK=
SK-MEL-24 M4eyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u5T2lEPTB;MD6xN|g4KM7:TR?= M{LHc3NCVkeHUh?=
LB831-BLC Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWToPItuUUN3ME2wMlE{QDh|IN88US=> M3rkS3NCVkeHUh?=
NCI-H2452 NFzNZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX36coRYUUN3ME2wMlE{QTV4IN88US=> MVHTRW5ITVJ?
RT-112 MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\LOYlKSzVyPUCuNVQxOzVizszN Moq5V2FPT0WU
GP5d NXrtOoFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYK5cYFzUUN3ME2wMlE1OTB2IN88US=> M4G5PXNCVkeHUh?=
LC-2-ad M2nYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[5N21pUUN3ME2wMlE1OTJzIN88US=> MoDmV2FPT0WU
MPP-89 M4LwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjlN3VpUUN3ME2wMlE1OTJ3IN88US=> NFvKdI9USU6JRWK=
NUGC-3 MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnre5VkUUN3ME2wMlE1PDd6IN88US=> MYTTRW5ITVJ?
GI-1 M4[yV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTiN2VKSzVyPUCuNVQ2PThizszN MmjNV2FPT0WU
HCC1419 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTp[mJ{UUN3ME2wMlE1PTd4IN88US=> MXTTRW5ITVJ?
SW1573 NGjxVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D3TGlEPTB;MD6xOFc2QCEQvF2= NHTYOIZUSU6JRWK=
NCI-H2347 NGLTN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7oTWM2OD1yLkG0PFM6KM7:TR?= MVfTRW5ITVJ?
Mewo Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF70cJFKSzVyPUCuNVQ5QDlizszN MUDTRW5ITVJ?
639-V MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm4TWM2OD1yLkG1NFE{KM7:TR?= M4HGOnNCVkeHUh?=
AsPC-1 Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFewcIZKSzVyPUCuNVUzOjVizszN NYHEN4toW0GQR1XS
NCI-H1648 MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnITWM2OD1yLkG1NlMzKM7:TR?= NX\4VYo2W0GQR1XS
786-0 MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HkcWlEPTB;MD6xOVM5OSEQvF2= M4nCNHNCVkeHUh?=
ETK-1 M2f1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwMUW5JO69VQ>? MnvZV2FPT0WU
BxPC-3 M2fmbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMUW5OlYh|ryP M4HqPHNCVkeHUh?=
CAL-62 Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXOd|BKSzVyPUCuNVYyPjlizszN M3jRNHNCVkeHUh?=
HCC1937 NHn6eVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;4bmhKSzVyPUCuNVYzPzVizszN Ml7nV2FPT0WU
NCI-H1299 NYTYeoxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M332UWlEPTB;MD6xOlI5PSEQvF2= NH[zS3dUSU6JRWK=
SW1088 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMU[0NVMh|ryP NFfWbFNUSU6JRWK=
FTC-133 NGrkXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO5TolrUUN3ME2wMlE3PTRizszN Mn;DV2FPT0WU
OC-314 M3TRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwMU[2PUDPxE1? M2j1e3NCVkeHUh?=
SCC-9 NX7leHNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy5PWVtUUN3ME2wMlE3PzF4IN88US=> MWPTRW5ITVJ?
HT-1376 NVzZZoUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMU[5N|Yh|ryP MlK3V2FPT0WU
U-2-OS MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HaUWlEPTB;MD6xO|E4OyEQvF2= NH;0dGNUSU6JRWK=
COLO-824 NXzHSGJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2GwdGlEPTB;MD6xO|I6PCEQvF2= Mo\QV2FPT0WU
BB30-HNC M3W0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj3TWM2OD1yLkG3N|Mh|ryP MU\TRW5ITVJ?
NCI-H2087 M3myfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH6XXRKSzVyPUCuNVc{PjhizszN MX\TRW5ITVJ?
NCI-H2170 NG[2cXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTsTWM2OD1yLkG3OVM3KM7:TR?= NV;oVYpOW0GQR1XS
SK-OV-3 NVrPSJdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DBRWlEPTB;MD6xO|U4OSEQvF2= NYrmOplDW0GQR1XS
MZ7-mel MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXDTWM2OD1yLkG3OlQ6KM7:TR?= NVT1OlZCW0GQR1XS
NCI-H650 NH;sZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWWz[oNDUUN3ME2wMlE4Pjh{IN88US=> NGnRdIRUSU6JRWK=
KOSC-2 NH;KdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMUe3N|Qh|ryP NVT0dZFPW0GQR1XS
SCC-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTVTWM2OD1yLkG3O|c4KM7:TR?= M1LzSHNCVkeHUh?=
MDA-MB-157 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMUiwPFIh|ryP MYjTRW5ITVJ?
KYSE-520 NH61S4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPCTWM2OD1yLkG4NkDPxE1? MoDNV2FPT0WU
LK-2 M4jzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPZTWM2OD1yLkG4N|A{KM7:TR?= MXrTRW5ITVJ?
KNS-81-FD M2DUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPMV3VJUUN3ME2wMlE5Ozl2IN88US=> MkHTV2FPT0WU
IGROV-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzPemY4UUN3ME2wMlE5PDR|IN88US=> NWT6cWc3W0GQR1XS
DEL NV\SRpZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfMTWM2OD1yLkG4OFUh|ryP NWPrVWNPW0GQR1XS
NCI-H1395 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X5OGlEPTB;MD6xPFY5OiEQvF2= NFPLRXJUSU6JRWK=
JEG-3 NV7XT2lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPOSYVIUUN3ME2wMlE5PzB3IN88US=> MmjNV2FPT0WU
BCPAP NVHVNXA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGCyblBKSzVyPUCuNVg5PzJizszN M3;BUXNCVkeHUh?=
CAL-27 M1vFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7DTWM2OD1yLkG5NFIzKM7:TR?= NYXPdFY5W0GQR1XS
RD M1zicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMUmxNVMh|ryP NXu4bGZWW0GQR1XS
RVH-421 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\uTWM2OD1yLkG5NVE3KM7:TR?= NFjkd3JUSU6JRWK=
Capan-2 M2\lT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMUmyOVYh|ryP MW\TRW5ITVJ?
COLO-680N NXvWcHR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXCTWM2OD1yLkG5N|Y1KM7:TR?= NFqyUmRUSU6JRWK=
NCI-H1650 NIfuempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrkTWM2OD1yLkKwNFU4KM7:TR?= MYrTRW5ITVJ?
SBC-5 NVPoTIw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknDTWM2OD1yLkKwNVE5KM7:TR?= MU\TRW5ITVJ?
U031 NHvvRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;GO|lKSzVyPUCuNlA2PDdizszN M{XJ[HNCVkeHUh?=
S-117 MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3iyfmlEPTB;MD6yNFU3PCEQvF2= MVzTRW5ITVJ?
DoTc2-4510 NYXRUJpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K0cmlEPTB;MD6yNFc3QSEQvF2= M3HOO3NCVkeHUh?=
AM-38 MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMkC4OFgh|ryP NYjXO5JNW0GQR1XS
A172 M3;Qemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMkGwNlIh|ryP MXHTRW5ITVJ?
HPAF-II NH3wNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD3WppuUUN3ME2wMlIyOjZ2IN88US=> M2HNPHNCVkeHUh?=
769-P NYK2TlZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;o[WlEPTB;MD6yNVI5KM7:TR?= NUn0SGlCW0GQR1XS
MFE-280 Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzxeoRKSzVyPUCuNlEzQThizszN MY\TRW5ITVJ?
TE-9 NIexTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\X[2lEPTB;MD6yNVc5PiEQvF2= MYXTRW5ITVJ?
C2BBe1 NVPV[4l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDlTWM2OD1yLkKyNVkh|ryP MnntV2FPT0WU
EoL-1-cell MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DleWlEPTB;MD6yNlIxOyEQvF2= NUn6d4pYW0GQR1XS
G-361 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMkK2PFIh|ryP NEjk[FZUSU6JRWK=
KYSE-270 Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\iUmVOUUN3ME2wMlI{ODh2IN88US=> MVvTRW5ITVJ?
TK10 M2PR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLCTWM2OD1yLkKzNVE4KM7:TR?= M13BdnNCVkeHUh?=
ML-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMkOxNVkh|ryP Mn\zV2FPT0WU
MHH-ES-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPYSFhKSzVyPUCuNlM3QDFizszN MVzTRW5ITVJ?
BHY MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGraS5ZKSzVyPUCuNlM3QTFizszN MYDTRW5ITVJ?
LS-513 M{PGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV63TY9pUUN3ME2wMlI{QTZzIN88US=> MUDTRW5ITVJ?
COLO-678 NGe5R4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwMkSwOFQh|ryP M1;qVnNCVkeHUh?=
NCI-H747 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\ZfJZ2UUN3ME2wMlI1OTZ7IN88US=> MW\TRW5ITVJ?
K5 M1XPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIH3dFBKSzVyPUCuNlQ{QCEQvF2= NFnXcoNUSU6JRWK=
OS-RC-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\mbY9KSzVyPUCuNlQ2ODlizszN MXPTRW5ITVJ?
KINGS-1 M4XCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMkS1Nlkh|ryP MV;TRW5ITVJ?
SCC-25 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV23OlhnUUN3ME2wMlI1PTZ|IN88US=> M{DZRnNCVkeHUh?=
CAPAN-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojwTWM2OD1yLkK0O|g{KM7:TR?= MmfPV2FPT0WU
ESS-1 M1fwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfiTWM2OD1yLkK0PFA2KM7:TR?= NFPrdoNUSU6JRWK=
TE-6 NUPqdIpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPNTWM2OD1yLkK1O|Uh|ryP MYLTRW5ITVJ?
LB2518-MEL MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfYV3RKSzVyPUCuNlU4PzdizszN MUjTRW5ITVJ?
COLO-800 Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwMkW4NVIh|ryP MVjTRW5ITVJ?
LU-134-A NH7uVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjyU2lKSzVyPUCuNlYyOzZizszN NX60OGNbW0GQR1XS
NCI-H1155 NWTveYJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PHRWlEPTB;MD6yOlE3OiEQvF2= MWDTRW5ITVJ?
MFM-223 NELG[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjpRmRKSzVyPUCuNlY{PjNizszN MVjTRW5ITVJ?
HTC-C3 MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMk[1NFYh|ryP MXXTRW5ITVJ?
HCT-116 M{jZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO0TWM2OD1yLkK2OVk6KM7:TR?= MWLTRW5ITVJ?
Ca-Ski M1LvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwMk[2O|gh|ryP MnvjV2FPT0WU
SBC-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1i0S2lEPTB;MD6yOlc1OiEQvF2= NVnrSJJWW0GQR1XS
NB69 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fKVWlEPTB;MD6yO|A5PyEQvF2= MoTuV2FPT0WU
J82 NEDEc|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[0bnVbUUN3ME2wMlI4OjZ3IN88US=> NWHxSHlpW0GQR1XS
U-118-MG NWrUeZh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMke1O|kh|ryP NFvRSGxUSU6JRWK=
NCI-H1355 M17nc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHwTWM2OD1yLkK4NFc1KM7:TR?= M{L2dnNCVkeHUh?=
NCI-H1048 Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;DfXpKSzVyPUCuNlg6PTZizszN M{LhV3NCVkeHUh?=
SW954 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMkmyNlch|ryP NWWwfZBkW0GQR1XS
NMC-G1 NIfNRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PNcmlEPTB;MD6yPVI4PyEQvF2= NV7JW45wW0GQR1XS
SW1710 NVTlRm5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMkm0PVQh|ryP MnXkV2FPT0WU
KY821 M{XzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMkm4O|Ih|ryP NH;0[oRUSU6JRWK=
HCC38 MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rJXmlEPTB;MD6zNFA4QCEQvF2= NF;jUo9USU6JRWK=
NCI-SNU-5 M3\rUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n1ZmlEPTB;MD6zNFU1KM7:TR?= NIC1fVZUSU6JRWK=
ES8 NEnOeZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fkS2lEPTB;MD6zNFc5PCEQvF2= NVTwOJB1W0GQR1XS
COLO-792 NVjUcIY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWm1enF4UUN3ME2wMlMyOjVzIN88US=> NIDUNHFUSU6JRWK=
BFTC-905 NHHlSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwM{G1NlEh|ryP NXzvc|RnW0GQR1XS
ChaGo-K-1 NH7pO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;mWoJKSzVyPUCuN|E4OTVizszN NHHwOGhUSU6JRWK=
Daoy M{j3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvlV2ZFUUN3ME2wMlMyPzJ|IN88US=> M135fnNCVkeHUh?=
SJSA-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwM{G4OFch|ryP Mm\VV2FPT0WU
KNS-62 Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;kUGlEPTB;MD6zNlA5QCEQvF2= NUXpPIZkW0GQR1XS
CAKI-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\abYhKSzVyPUCuN|IyOTFizszN NV33bmNpW0GQR1XS
UACC-62 NGC5TmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\TOlVKSzVyPUCuN|IzOjdizszN M13ETXNCVkeHUh?=
HuCCT1 NXW3VnBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrYeIFKSzVyPUCuN|IzQDNizszN MUTTRW5ITVJ?
CTB-1 MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwM{K3OVMh|ryP M3PSfHNCVkeHUh?=
NTERA-S-cl-D1 NIrPRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{GyR2lEPTB;MD6zNlg{PiEQvF2= NF3obo9USU6JRWK=
T-24 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\WXWlEPTB;MD6zN|E2QSEQvF2= MYHTRW5ITVJ?
KYSE-70 M3r0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHSTWM2OD1yLkOzNlg{KM7:TR?= M1z5[3NCVkeHUh?=
SW626 NF7ie49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwM{O1N|Ih|ryP MnPkV2FPT0WU
LB996-RCC NF7IcXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Lz[GlEPTB;MD6zN|YyQSEQvF2= M4fTPHNCVkeHUh?=
DMS-273 MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwM{O5NVYh|ryP NFzQWZBUSU6JRWK=
SW1783 MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwM{O5PVch|ryP NY\3T5IxW0GQR1XS
KU812 NViwcWF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2WzUmlEPTB;MD6zOFA{QCEQvF2= NHPGWVNUSU6JRWK=
HSC-2 M4jVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXje|ZbUUN3ME2wMlM1ODV|IN88US=> Mn;kV2FPT0WU
A3-KAW MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWCzRWlsUUN3ME2wMlM1OTZ{IN88US=> NV;lTWJKW0GQR1XS
COLO-684 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfaRYlKSzVyPUCuN|Q2ODFizszN M1zZW3NCVkeHUh?=
NCI-H2405 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jCOmlEPTB;MD6zOFY{OSEQvF2= NYPJR3R4W0GQR1XS
NCI-H2228 M1LV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknETWM2OD1yLkO1N|U4KM7:TR?= NYjEdZBHW0GQR1XS
NB13 M{\0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[3XGlEPTB;MD6zOlgzQSEQvF2= NH;NbW1USU6JRWK=
no-11 MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T0W2lEPTB;MD6zOlk2KM7:TR?= NGfW[GZUSU6JRWK=
DK-MG M3XyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwM{exPFgh|ryP NH;TU2xUSU6JRWK=
NBsusSR NUXZ[m5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M36z[mlEPTB;MD6zO|I5PSEQvF2= NHTjT49USU6JRWK=
KP-N-YS NIXqUJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwM{e0OlMh|ryP MlSzV2FPT0WU
CFPAC-1 NWHiT|h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP6XY82UUN3ME2wMlM4PTF6IN88US=> M121cHNCVkeHUh?=
KARPAS-45 NXGxfIgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTQTWM2OD1yLkO3PFYzKM7:TR?= MlvOV2FPT0WU
NCI-H1793 NUfG[4NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP0eJJDUUN3ME2wMlM5PTFizszN NH\oe4xUSU6JRWK=
HCE-T MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;XSYZoUUN3ME2wMlM5PjB|IN88US=> NUXZblJJW0GQR1XS
NCI-H520 M2fs[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW5[Y9KSzVyPUCuN|g4ODNizszN MkLDV2FPT0WU
HCC2157 NYPLeXBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4CzTWlEPTB;MD6zPFc5OSEQvF2= NVvLUFZuW0GQR1XS
EW-18 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vycmlEPTB;MD6zPFk1OSEQvF2= NYO2O4R4W0GQR1XS
RO82-W-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwM{m2PVkh|ryP M2PjTXNCVkeHUh?=
HuP-T3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLRblh1UUN3ME2wMlQxOTR|IN88US=> Mn3yV2FPT0WU
PANC-10-05 NFrKS3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTZZXF[UUN3ME2wMlQyOTdizszN MWnTRW5ITVJ?
NCI-H1703 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i4eGlEPTB;MD60NVQ1PiEQvF2= MVPTRW5ITVJ?
TE-10 NF\Fb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\je2pKSzVyPUCuOFE1PDdizszN NGDweY9USU6JRWK=
HOS MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXPOZR2UUN3ME2wMlQyPjh{IN88US=> M1rhUXNCVkeHUh?=
LN-405 NYL2UZE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\ubogyUUN3ME2wMlQyPjh5IN88US=> MYHTRW5ITVJ?
A427 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfVeFFRUUN3ME2wMlQyQThzIN88US=> MXfTRW5ITVJ?
CAL-12T MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fCNWlEPTB;MD60Nlc5KM7:TR?= NX:5NHdnW0GQR1XS
SW756 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfiTWM2OD1yLkS0NVg{KM7:TR?= M{XIcHNCVkeHUh?=
YAPC Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\hTWM2OD1yLkS1NFgh|ryP M1nuRXNCVkeHUh?=
GOTO NF;VO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPGc4FKSzVyPUCuOFUyPiEQvF2= M1zkPHNCVkeHUh?=
C3A MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXO5PZBMUUN3ME2wMlQ2PDN5IN88US=> M2j0W3NCVkeHUh?=
UM-UC-3 MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LQUGlEPTB;MD60OVQ4KM7:TR?= MYfTRW5ITVJ?
NCI-H1573 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TJc2lEPTB;MD60OVU3QSEQvF2= MkLEV2FPT0WU
LS-411N NYW1bYpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn24TWM2OD1yLkS2OVI4KM7:TR?= MVjTRW5ITVJ?
COR-L23 M2W5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHIb4hzUUN3ME2wMlQ3PzZ2IN88US=> M3LHUnNCVkeHUh?=
HCE-4 NV;BNWxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnsOWtVUUN3ME2wMlQ4PDR4IN88US=> MmjBV2FPT0WU
NCI-H2291 NVi1d5hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwNEe4PVYh|ryP NInYWXdUSU6JRWK=
A101D M1TXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm5TWM2OD1yLkS4NFU{KM7:TR?= NV7nPWxEW0GQR1XS
HT-3 NXfUV5RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4frZmlEPTB;MD60PFIyPyEQvF2= NF3EO2JUSU6JRWK=
HOP-62 NILUOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT0TWM2OD1yLkS5PFY2KM7:TR?= M{LYR3NCVkeHUh?=
PC-3 NVLze5hNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3oZXUxUUN3ME2wMlUyPTB5IN88US=> NXPMW5l1W0GQR1XS
CTV-1 NVvWN5FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrNS5VKSzVyPUCuOVI3PjlizszN MXrTRW5ITVJ?
PANC-08-13 M3\xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK2TWM2OD1yLkWzNVc4KM7:TR?= NFntPZpUSU6JRWK=
CAL-120 M4XteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:4e5hKSzVyPUCuOVM{QTlizszN M2j4SXNCVkeHUh?=
UMC-11 NXvmUYRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rle2lEPTB;MD61OVI{PCEQvF2= MYLTRW5ITVJ?
MSTO-211H NXizUYNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwNUW3OlIh|ryP NEjHWFNUSU6JRWK=
NCI-H2126 MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwNU[4NVUh|ryP M2rqWHNCVkeHUh?=
SNU-C2B M2jzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XFV2lEPTB;MD61O|k4PyEQvF2= MnPsV2FPT0WU
DBTRG-05MG MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwNUiwOVMh|ryP NIXPN4ZUSU6JRWK=
MKN1 NWnzSpM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnKwTWM2OD1yLkW4O|g{KM7:TR?= M{CxRnNCVkeHUh?=
ES3 NIOwU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LUUGlEPTB;MD61PVEzPCEQvF2= MYDTRW5ITVJ?
OVCAR-3 M1WwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3iTWM2OD1yLkW5N|QyKM7:TR?= MmmyV2FPT0WU
ACHN Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HFXWlEPTB;MD62NFU3QSEQvF2= M1HvUXNCVkeHUh?=
SW872 MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTvOYFWUUN3ME2wMlYxPzZ|IN88US=> NUPndFAyW0GQR1XS
CP66-MEL MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnHPW9KSzVyPUCuOlA6PjlizszN M{PjfHNCVkeHUh?=
NCI-H661 MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jnZWlEPTB;MD62NVExPCEQvF2= M{\GNXNCVkeHUh?=
UACC-893 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzVTWM2OD1yLk[zOlgyKM7:TR?= MWjTRW5ITVJ?
JVM-3 MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3GTWM2OD1yLk[zPFA1KM7:TR?= MVjTRW5ITVJ?
SF268 NHTGOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXkcmlKSzVyPUCuOlQ{PDlizszN NV2wcVhDW0GQR1XS
OCI-AML2 M331fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnFdGgxUUN3ME2wMlY2Ozl5IN88US=> NFzsdmxUSU6JRWK=
RPMI-8226 Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17y[2lEPTB;MD62OlMzOyEQvF2= NVzzcFBtW0GQR1XS
MKN28 M3jlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwNk[2NlQh|ryP M37VZ3NCVkeHUh?=
MDA-MB-453 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwNkexPEDPxE1? NYS4cplPW0GQR1XS
BV-173 NFLjUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj3eIxHUUN3ME2wMlY5Pjd7IN88US=> NY\lT5ZbW0GQR1XS
NCI-H358 M1zh[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjRUY9FUUN3ME2wMlY5PzJ4IN88US=> NX7ISIdGW0GQR1XS
NCI-H1651 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzzOHpKSzVyPUCuO{DPxE1? MVfTRW5ITVJ?
MDA-MB-415 NHzv[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwN{C4Nlkh|ryP NHT1b4ZUSU6JRWK=
8305C NV3Qc4pCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm2fJBKSzVyPUCuO|I1QThizszN MoDlV2FPT0WU
EFM-19 NWHabZVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\vN3VKSzVyPUCuO|M3PzFizszN Mo\vV2FPT0WU
RERF-LC-MS NHHnNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTXTWM2OD1yLke0OlE{KM7:TR?= NIDwXIxUSU6JRWK=
A388 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn0cZBlUUN3ME2wMlc3PDZ5IN88US=> NWe5TY1EW0GQR1XS
GI-ME-N NY\tUWVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwN{eyN|Uh|ryP M2j4VHNCVkeHUh?=
IGR-1 NEj3TZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nkV2lEPTB;MD63PVA1OyEQvF2= M4j3UXNCVkeHUh?=
LNCaP-Clone-FGC M2jMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDxTWM2OD1yLkiwNFA1KM7:TR?= MWrTRW5ITVJ?
SK-MEL-3 MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3m5WGlEPTB;MD64NVUxQCEQvF2= M33YenNCVkeHUh?=
UACC-257 NW[wOohPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPaTWM2OD1yLkiyNlMyKM7:TR?= NISwUolUSU6JRWK=
OE33 M4roeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW4ZYM{UUN3ME2wMlg2OTBzIN88US=> MY\TRW5ITVJ?
QIMR-WIL NFGxSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\mcmlEPTB;MD64OVE1OSEQvF2= NGXmN41USU6JRWK=
NCI-H2009 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13OWGlEPTB;MD64OVMyOSEQvF2= MYHTRW5ITVJ?
NCI-H522 M1POOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW1TWM2OD1yLki3O|g{KM7:TR?= NYPPSZhTW0GQR1XS
Saos-2 MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;RPWlEPTB;MD64O|g4OSEQvF2= NFXKZ2NUSU6JRWK=
NB17 NHvRNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknvTWM2OD1yLki4NFI2KM7:TR?= M37TZXNCVkeHUh?=
D-392MG MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwOEmzOVYh|ryP MV;TRW5ITVJ?
SHP-77 NFHRXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEKxVGZKSzVyPUCuPVA1QDVizszN NYr2WnVJW0GQR1XS
SK-MEL-30 NHLid5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwOUGxPFUh|ryP MmXEV2FPT0WU
GCIY MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\LTWM2OD1yLkmxPFQ{KM7:TR?= NHezcFdUSU6JRWK=
HCC70 NXvtcXpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnrZVY6UUN3ME2wMlkzODV7IN88US=> MlHhV2FPT0WU
LU-65 M4DKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwOUK1PVEh|ryP MXLTRW5ITVJ?
NCI-H1563 NYXYfFRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;GO|lCUUN3ME2wMlk1QDZ3IN88US=> MWfTRW5ITVJ?
KURAMOCHI MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwOUWxPVIh|ryP MnnYV2FPT0WU
PA-1 MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3FPGxKSzVyPUCuPVU1OjRizszN NUD3bZAzW0GQR1XS
NOS-1 NGDQV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2OydWlEPTB;MD65O|Q5QSEQvF2= M1\LfHNCVkeHUh?=
NCI-H69 M1vHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL3TWM2OD1yLkm3OlM1KM7:TR?= NEHXbpZUSU6JRWK=
KYSE-450 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH3TWM2OD1yLkm4OlI3KM7:TR?= MYDTRW5ITVJ?
8505C NYjhUGhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;Oe4pEUUN3ME2wMlk6QTh{IN88US=> NV;xV|UzW0GQR1XS
TGBC24TKB MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSyTWM2OD1zLkCwNFg1KM7:TR?= NYO1TXpPW0GQR1XS
PFSK-1 M2f2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPkZmpKSzVyPUGuNFE1OjhizszN MWfTRW5ITVJ?
EKVX M3TYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnDdYdKSzVyPUGuNFMyOjFizszN M3;SVnNCVkeHUh?=
RCM-1 NUDPZY52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTFwMEW1NFch|ryP M37CdnNCVkeHUh?=
SW900 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDDd2JKSzVyPUGuNFc5OyEQvF2= NGjjNIRUSU6JRWK=
D-542MG M2To[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2SxbmlEPTB;MT6wO|g2PSEQvF2= MW\TRW5ITVJ?
SK-PN-DW M2DYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3FTWM2OD1zLkGwNFU3KM7:TR?= MWTTRW5ITVJ?
NCI-H727 M{e1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG3Tm1KSzVyPUGuNVAyPTRizszN NXjNUYZZW0GQR1XS
SW837 M1fNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfmU3ZKSzVyPUGuNVA6PTRizszN NHTHSY5USU6JRWK=
BT-20 M1K3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljNTWM2OD1zLkGxNlA1KM7:TR?= NH7RTHVUSU6JRWK=
RH-18 NVT5VlVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLaTWM2OD1zLkGzNVA{KM7:TR?= NWDzcpEzW0GQR1XS
TE-12 M1LqTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;jbVd2UUN3ME2xMlE{OzN|IN88US=> NIXHS4RUSU6JRWK=
NB10 NWjU[o82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS5fGpjUUN3ME2xMlE{OzR2IN88US=> Ml3UV2FPT0WU
AU565 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFwMUW5O|Mh|ryP NG\EU3JUSU6JRWK=
OAW-42 NV62T41ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFwMUizNFYh|ryP NV71O2ZqW0GQR1XS
DJM-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln0TWM2OD1zLkG5PFgyKM7:TR?= NE\LS3BUSU6JRWK=
HH NHjYNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDuTWM2OD1zLkKzPFMyKM7:TR?= Ml\2V2FPT0WU
LAMA-84 MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDHTWM2OD1zLkK3N|k1KM7:TR?= MV\TRW5ITVJ?
KNS-42 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPvOGtKSzVyPUGuN|AzQTZizszN M4O4eHNCVkeHUh?=
NCI-H2052 M2jZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3K0TmlEPTB;MT6zNFUxPyEQvF2= MUTTRW5ITVJ?
MLMA M2H5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFwM{K0NFch|ryP NGW2WlVUSU6JRWK=
NB12 MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTFwM{W2N|Yh|ryP NWT3[XJkW0GQR1XS
NCI-H1838 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjtdmxkUUN3ME2xMlM3OzB4IN88US=> M2XPOXNCVkeHUh?=
NCI-H526 M1HRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnMcXB[UUN3ME2xMlM4QDV|IN88US=> Mo\oV2FPT0WU
LS-123 MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr6TWM2OD1zLkO5NFk1KM7:TR?= NXP3dpFsW0GQR1XS
HDLM-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjiTWM2OD1zLkO5NlcyKM7:TR?= M2G1eHNCVkeHUh?=
MC-IXC NEDqR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PkZ2lEPTB;MT60NlM4OSEQvF2= NF3RcodUSU6JRWK=
HCT-15 M2DDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLKTWM2OD1zLkSzNFY5KM7:TR?= NV\qNZAzW0GQR1XS
NCI-H596 NUX3c3pYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXF[GhKSzVyPUGuOFUxPjFizszN NV7DV|diW0GQR1XS
ZR-75-30 NILrXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W5WGlEPTB;MT60O|A5OiEQvF2= MXTTRW5ITVJ?
A704 NEXHc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFSwWWFKSzVyPUGuOlY2PjNizszN NGfnUG1USU6JRWK=
OVCAR-4 MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{C0cmlEPTB;MT62PVYxPyEQvF2= MUnTRW5ITVJ?
SW1417 NWTKNmhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\rR|lYUUN3ME2xMlczQDR7IN88US=> NXzvemFvW0GQR1XS
CAS-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFwN{O5N|Yh|ryP M4rXWHNCVkeHUh?=
IST-SL1 MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX1TWM2OD1zLke5O|U6KM7:TR?= M17S[XNCVkeHUh?=
A253 NHrPTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jKb2lEPTB;MT64NlI{QSEQvF2= NEC4bVRUSU6JRWK=
EW-16 MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[wTWM2OD1zLkiyPFc2KM7:TR?= M2q1U3NCVkeHUh?=
SK-NEP-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3IflJKSzVyPUGuPFY6QDhizszN NIrtPVVUSU6JRWK=
NCI-H226 MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFwOEmzOVkh|ryP M13JNHNCVkeHUh?=
HOP-92 NIS2SWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDYTWM2OD1zLkm2NFk6KM7:TR?= M1:0O3NCVkeHUh?=
NCI-H441 NIS4SJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjNOJpKSzVyPUKuNFI{OzdizszN NWHPSJV{W0GQR1XS
LU-139 NGr4[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTpTWM2OD1{LkCzNVE1KM7:TR?= MknsV2FPT0WU
SJRH30 Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJwMESyOVMh|ryP MXXTRW5ITVJ?
MG-63 M1m3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjWTWM2OD1{LkG0NVEyKM7:TR?= MoPRV2FPT0WU
NH-12 NGroV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L3TmlEPTB;Mj6xOVAxPiEQvF2= M3XWfXNCVkeHUh?=
NB7 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVi2[FA4UUN3ME2yMlE6Pjd|IN88US=> MYjTRW5ITVJ?
LB771-HNC NFvrVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK3OJFKSzVyPUKuNlA2QTVizszN M3rXcnNCVkeHUh?=
HCC1569 M4C5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnHTWM2OD1{LkK0OVg{KM7:TR?= MljFV2FPT0WU
D-283MED MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLKdohtUUN3ME2yMlI1Pzh{IN88US=> M2T6TnNCVkeHUh?=
J-RT3-T3-5 NGfxVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\wPFNKSzVyPUKuNlU{PTFizszN MWTTRW5ITVJ?
ATN-1 MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13rXWlEPTB;Mj6zN|A5OiEQvF2= NHHNVo9USU6JRWK=
HCC1954 NIf0dG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJwM{S0NFgh|ryP NYT1RXliW0GQR1XS
SCC-15 M{C3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX2zSWt1UUN3ME2yMlM6OzF{IN88US=> MonUV2FPT0WU
COLO-668 NW[4WZlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjESIFKSzVyPUKuOFMzKM7:TR?= NYTWRXRYW0GQR1XS
LB373-MEL-D MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6zfGxKSzVyPUKuOVQ3PzdizszN MWnTRW5ITVJ?
no-10 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPER21KSzVyPUKuOVQ6PDdizszN NYnINZROW0GQR1XS
HT-1197 NXXtR3NlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJwNkOxPFgh|ryP MVvTRW5ITVJ?
DU-145 NXXqbpZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33JO2lEPTB;Mj63PVE3OiEQvF2= MomxV2FPT0WU
SK-N-AS M{LLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH31XG1KSzVyPUKuPFQ3QTJizszN Mnv6V2FPT0WU
MOLT-4 MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfuc4NkUUN3ME2yMlg2OzJ{IN88US=> NFvibG1USU6JRWK=
EW-22 NXLEe41tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJwOUK4OFEh|ryP NIf1SWxUSU6JRWK=
DB M4j2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJwOUe3OVkh|ryP NETZVpFUSU6JRWK=
HL-60 NGqwNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLsZ|VDUUN3ME2zMlA1Ozd4IN88US=> NG[5RohUSU6JRWK=
SK-N-DZ M2PnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\Wdo5xUUN3ME2zMlA2ODd3IN88US=> M2jRO3NCVkeHUh?=
NY M1f3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXSSoVbUUN3ME2zMlA5PTR{IN88US=> Mki2V2FPT0WU
T47D NX[zdm9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PDbGlEPTB;Mz6xNFU2QCEQvF2= NE\MeWhUSU6JRWK=
NCI-H2029 NXjLe41GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnkR5NNUUN3ME2zMlIzPDd5IN88US=> MknkV2FPT0WU
KARPAS-299 MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTNwMk[wNlch|ryP MorVV2FPT0WU
KM-H2 NYHBc2RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3TTWM2OD1|LkOwOlgh|ryP MnT0V2FPT0WU
CHP-134 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTNwNEezPUDPxE1? Mnj4V2FPT0WU
22RV1 M2P5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T3OmlEPTB;Mz60PVE3QCEQvF2= NVrDPXVXW0GQR1XS
NB5 MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfQOHZKSzVyPUOuOVA3QDlizszN MnfxV2FPT0WU
CW-2 NXTofFlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrnfGVKSzVyPUOuOVU{OTRizszN NX\vW2hvW0GQR1XS
EFO-21 MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2frNGlEPTB;Mz61Olk1KM7:TR?= MlLpV2FPT0WU
HuH-7 NXnoOoR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDBTWM2OD1|LkW4OFE1KM7:TR?= MkTKV2FPT0WU
ALL-PO MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjITWM2OD1|Lk[yN|M2KM7:TR?= MYDTRW5ITVJ?
EM-2 NXTtdHNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XtXWlEPTB;Mz62PVAyOSEQvF2= Mn\RV2FPT0WU
KLE MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn2TWM2OD1|LkezNFI6KM7:TR?= M1TOOnNCVkeHUh?=
NEC8 NVj0ZVFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;kfZhpUUN3ME2zMlkyQDB6IN88US=> M1niOHNCVkeHUh?=
KP-N-YN MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37zc2lEPTB;Mz65N|Q4PiEQvF2= MYTTRW5ITVJ?
SK-MEL-1 MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDZXlJkUUN3ME20MlA{PTF6IN88US=> M2nH[HNCVkeHUh?=
CAL-54 Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHGTWM2OD12LkC1PVEh|ryP NFS0[3BUSU6JRWK=
MS-1 Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvRdYFIUUN3ME20MlE3OTV3IN88US=> Mk\BV2FPT0WU
NCI-H209 M4m5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIKwb2hKSzVyPUSuNlk6QTlizszN NWTJPJhFW0GQR1XS
NOMO-1 NHjOT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTRwM{KxN|Eh|ryP M33JTHNCVkeHUh?=
RPMI-2650 M2PPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF6wUVdKSzVyPUSuN|Y{OjdizszN M3f1N3NCVkeHUh?=
NCI-H810 NEPYfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrpTWM2OD12LkO5O|M3KM7:TR?= MnnBV2FPT0WU
Ca9-22 MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrXTYNKSzVyPUSuOFU3QTFizszN M{nZT3NCVkeHUh?=
ES4 M3PVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[y[lZKSzVyPUSuOFcxQTVizszN NFj1fm5USU6JRWK=
ES6 M2TxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTRwNEm2OVch|ryP MVPTRW5ITVJ?
DMS-114 M{Xwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzmXol5UUN3ME20MlU1PjlzIN88US=> MkX0V2FPT0WU
ONS-76 NXzFN5FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLCb2ZCUUN3ME20MlU4QTVizszN M{fFNXNCVkeHUh?=
K-562 NIPEe4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrwTWM2OD12LkezPFE1KM7:TR?= MlvwV2FPT0WU
MHH-NB-11 M2i4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1GxfWlEPTB;ND63OVQ3OSEQvF2= NV;lcJhLW0GQR1XS
Calu-3 MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fKb2lEPTB;ND63PFU1QCEQvF2= MWDTRW5ITVJ?
HT55 NH;vXWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPXTWM2OD12Lki0OVQ2KM7:TR?= M{DXbXNCVkeHUh?=
SK-N-FI NI\qUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDUO29KSzVyPUSuPFUxODlizszN NHjQS4hUSU6JRWK=
ES1 NFLsVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHtcW1HUUN3ME20Mlg3ODV5IN88US=> NXGwXlkyW0GQR1XS
SF126 NWnOVHRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTKTWM2OD12LkmzNVg1KM7:TR?= MVXTRW5ITVJ?
ES5 NEOwZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3tWmVPUUN3ME21MlEzPDJ5IN88US=> NFPGOoxUSU6JRWK=
LoVo M2DTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny1TWM2OD13LkG1PFcyKM7:TR?= M{S0VnNCVkeHUh?=
SNU-387 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\TXVI6UUN3ME21MlMzOzN7IN88US=> NFnKVWZUSU6JRWK=
C8166 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTVwM{[zN|kh|ryP MUjTRW5ITVJ?
LS-1034 MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTVwNEKzNFch|ryP Mn\nV2FPT0WU
GR-ST NHnCTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmiwTWM2OD13LkWyNlAyKM7:TR?= NF7Mc|RUSU6JRWK=
NCI-H1092 NGXjeW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK2TWM2OD13LkeyPFQ{KM7:TR?= MmjqV2FPT0WU
647-V NYHpPWp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{exUmlEPTB;NT63OFcxPiEQvF2= NE[zcGhUSU6JRWK=
EW-13 Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTVwN{[2Nlch|ryP MYrTRW5ITVJ?
KGN M1rzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\reGlEPTB;Nj6wPVkzOSEQvF2= M3W5THNCVkeHUh?=
D-423MG NH24NHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe1To5KSzVyPU[uOFAzQDRizszN MkCxV2FPT0WU
ECC10 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzGfGtiUUN3ME23MlExOTBzIN88US=> M1LyZnNCVkeHUh?=
TE-5 NXXGXGd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf2NWtjUUN3ME23MlQyOjl6IN88US=> NHmzVpJUSU6JRWK=
P12-ICHIKAWA M324cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULJZnZ[UUN3ME23MlQ2PTJ|IN88US=> MmrDV2FPT0WU
NCI-H82 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFq1VmJKSzVyPUeuOFU4ODFizszN MmfSV2FPT0WU
NCI-H1993 NH\ZfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;qb4tKSzVyPUeuPFMxPjNizszN NVjjb4YyW0GQR1XS
RH-1 NWrTe4ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTdwOEWyOFQh|ryP MYTTRW5ITVJ?
SW948 M32yT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLmTWM2OD15Lkm2NFQ6KM7:TR?= M3fMRXNCVkeHUh?=
CAL-33 NV7BeXg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3yxR2lEPTB;Nz65PVk{QCEQvF2= MYHTRW5ITVJ?
U-266 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvZNXpKSzVyPUiuNVU4PzdizszN M3;YbHNCVkeHUh?=
CAL-72 M3fmNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRThwMkCzNkDPxE1? MmXpV2FPT0WU
SNU-423 MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTlwM{[2OlYh|ryP MljHV2FPT0WU
KG-1 NXfHdJdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXWTWM2OD17LkW4OFU3KM7:TR?= MX7TRW5ITVJ?
HCC1395 NHjNVWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTlwOUKzOVIh|ryP MXnTRW5ITVJ?
BE-13 M3fxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvoTWM2OD1zMD64PFkzKM7:TR?= M32zNHNCVkeHUh?=
MKN7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFyLkm3OlUh|ryP NIT5NopUSU6JRWK=
697 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\5V4RXUUN3ME2xNU4yPDd{IN88US=> MonLV2FPT0WU
LU-135 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvOTWM2OD1zMT6yN|A4KM7:TR?= MoTJV2FPT0WU
ES7 NFzEdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Ppb2lEPTB;MUGuN|MyOyEQvF2= M1rNT3NCVkeHUh?=
SK-HEP-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfKTWM2OD1zMT63OlQ3KM7:TR?= MUfTRW5ITVJ?
BEN MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTFzLki1NUDPxE1? MljVV2FPT0WU
NCI-H1770 NH7W[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTF{LkGyOkDPxE1? MYHTRW5ITVJ?
SW13 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHHZnBKSzVyPUGyMlE2PDFizszN M4HFNXNCVkeHUh?=
MZ1-PC M1Xhe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[zPW1KSzVyPUGyMlU1PTJizszN NGXReoNUSU6JRWK=
Mo-T MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlWzTWM2OD1zMj63OFIyKM7:TR?= MnjsV2FPT0WU
HLE M1\sT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHOxT5FKSzVyPUGyMlgzOTVizszN NXv0PZAxW0GQR1XS
RCC10RGB NHvjb2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnzTWM2OD1zMz62O|Eh|ryP MV7TRW5ITVJ?
COLO-320-HSR M4fsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnJe5lKSzVyPUGzMlc{QDFizszN NYi3WlJvW0GQR1XS
BHT-101 NFmz[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPqTWM2OD1zMz64N|Q2KM7:TR?= M1XU[3NCVkeHUh?=
OCUB-M MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1iwSmlEPTB;MUSuNVYxOiEQvF2= MofWV2FPT0WU
MEG-01 M4rXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7zWZVKSzVyPUG0MlM4ODhizszN M37KOHNCVkeHUh?=
RS4-11 NIi3WplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTlTWM2OD1zND63OFIh|ryP NEW4cYdUSU6JRWK=
MN-60 NXTZe45rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF2Lke4PVQh|ryP NWLvVXNlW0GQR1XS
NCI-H1304 Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF3LkC0NlUh|ryP M4HETnNCVkeHUh?=
Ramos-2G6-4C10 NV:zfFJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvobZh4UUN3ME2xOU4xPThzIN88US=> MofxV2FPT0WU
NCI-H2342 MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF3LkKwOFQh|ryP MUPTRW5ITVJ?
LAN-6 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLtTWM2OD1zNT60OFE1KM7:TR?= MVrTRW5ITVJ?
JVM-2 NXjRZpNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDETWM2OD1zNT61O|Q5KM7:TR?= MnfCV2FPT0WU
P30-OHK NWf0eW9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XjUGlEPTB;MU[uNFYyPCEQvF2= MXHTRW5ITVJ?
C-33-A NGj4UoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O1SmlEPTB;MU[uOlIyPCEQvF2= NEjjdo1USU6JRWK=
RPMI-8866 NXHJPGhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF4Lki0PVYh|ryP NIrUNlBUSU6JRWK=
NCI-H630 NHXzRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT4[YpxUUN3ME2xOk45PTN5IN88US=> NEixeFZUSU6JRWK=
KYSE-140 M1Tsc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O1TGlEPTB;MUeuNlAzQCEQvF2= M2\ZUnNCVkeHUh?=
T84 NWrZbVI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTTTWM2OD1zOD64Olk2KM7:TR?= NHnxboxUSU6JRWK=
KU-19-19 M1rCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTPWHBKSzVyPUG4Mlk3ODhizszN MoXiV2FPT0WU
BALL-1 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF7LkOzPVkh|ryP M4LHRnNCVkeHUh?=
Calu-6 NHjHOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHexT|lKSzVyPUG5MlQ6OiEQvF2= M3fFdHNCVkeHUh?=
EGI-1 MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLyTWM2OD1zOT61PVgh|ryP M3H0Z3NCVkeHUh?=
MFH-ino Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rEZ2lEPTB;MUmuO|Q2PCEQvF2= NGHqRXpUSU6JRWK=
GB-1 NHjrXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{excmlEPTB;MkCuN|U{PSEQvF2= NGXUV3RUSU6JRWK=
NCI-H1693 M2L6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPVbW1jUUN3ME2yNE43PTB3IN88US=> NEjpcGpUSU6JRWK=
SW1116 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfKTWM2OD1{MD65N|YzKM7:TR?= NVTKbnVuW0GQR1XS
H-EMC-SS NWf1WG9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofpTWM2OD1{Mj6wOFUh|ryP MlrnV2FPT0WU
D-502MG NUPiSZlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3frUGlEPTB;MkKuPFI3OSEQvF2= M{TaZXNCVkeHUh?=
IA-LM M1W4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJ|LkK0PVMh|ryP NHnVN5FUSU6JRWK=
SW1463 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1eyR2lEPTB;MkOuO|kh|ryP MoTvV2FPT0WU
JAR NXm5WlFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;NNVhQUUN3ME2yOE4{Ojl|IN88US=> M{PpcXNCVkeHUh?=
HT MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;wRWlEPTB;MkSuOFc2OyEQvF2= MV7TRW5ITVJ?
LCLC-103H NFrOTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nvT2lEPTB;MkSuPFQ1QSEQvF2= M2SzXHNCVkeHUh?=
SNU-449 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:3TWM2OD1{ND64O|QyKM7:TR?= M3T6RnNCVkeHUh?=
KE-37 M33wWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nhSmlEPTB;MkWuNFkzQCEQvF2= M1XQcHNCVkeHUh?=
NCI-H1623 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP6N5VKSzVyPUK3MlE{ODNizszN NHnhfmtUSU6JRWK=
MOLT-13 NEW5T2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3pTWM2OD1{Nz6zOVE3KM7:TR?= NUO3bo5ZW0GQR1XS
COLO-741 M2rjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NICwZmhKSzVyPUOxMlM{OzNizszN M{XNZXNCVkeHUh?=
NB6 NXPXd2JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTN{LkK4O|Yh|ryP NWP4TpRTW0GQR1XS
MOLT-16 M4rpd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnj[XBKSzVyPUOzMlAxPTVizszN M1G4RnNCVkeHUh?=
IST-MES1 Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS3bZdYUUN3ME2zOE4xPTRzIN88US=> NVnFTVdbW0GQR1XS
A4-Fuk M{f4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED1[ZVKSzVyPUO1MlA3PiEQvF2= M{i1WnNCVkeHUh?=
CAL-85-1 M1nF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofXTWM2OD1|NT6yPFE4KM7:TR?= NUHzO|BDW0GQR1XS
CCRF-CEM M2HtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTN5LkG1N|Yh|ryP MVXTRW5ITVJ?
HAL-01 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq2bYxKSzVyPUO4MlQ5QDlizszN MleyV2FPT0WU
HEL MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTR|LkO0NFkh|ryP MW\TRW5ITVJ?
EW-1 NELPWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\zUWlEPTB;NEOuOFc3QCEQvF2= NYDCXYxoW0GQR1XS
MDA-MB-231 M{Tocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL1TWM2OD12NT6xNVk6KM7:TR?= MVfTRW5ITVJ?
ABC-1 MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTR4Lki1N|gh|ryP MmfWV2FPT0WU
NCI-H446 NHi5c2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHLTWM2OD12OD61NFU5KM7:TR?= NX\UTm53W0GQR1XS
MHH-PREB-1 NYnjeHd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTR7Lk[wNFch|ryP MlrlV2FPT0WU
DOHH-2 MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfrV4o{UUN3ME20PU43PjV4IN88US=> MVLTRW5ITVJ?
GCT NU\TTnMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T3OGlEPTB;NEmuOlk4PiEQvF2= MX\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo 17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. [1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. [2]

Protocol

Kinase Assay:[1]
+ Expand

Hsp90 binding assays:

Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:[1]
+ Expand
  • Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 5 days
  • Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells is subtracted. Percentage of viable cells = (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6
  • Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle
  • Dosages: ~50 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (170.73 mM)
Ethanol 5 mg/mL (8.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+corn oil
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 585.69
Formula

C31H43N3O8

CAS No. 75747-14-7
Storage powder
in solvent
Synonyms CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00577889 Completed Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage IV Pancreatic Cancer National Cancer Institute (NCI) March 2008 Phase 2
NCT00546780 Completed Multiple Myeloma Bristol-Myers Squibb February 2008 Phase 3
NCT00093496 Completed Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer National Cancer Institute (NCI) October 2007 Phase 2
NCT00514371 Completed Multiple Myeloma Bristol-Myers Squibb August 2007 Phase 2|Phase 3
NCT00779428 Completed Advanced Malignancies Bristol-Myers Squibb July 2006 Phase 2
NCT00354185 Terminated Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor Protocol Specific|Waldenström Macroglobulinemia National Cancer Institute (NCI) May 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?

  • Answer:

    17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products4

Tags: buy Tanespimycin (17-AAG) | Tanespimycin (17-AAG) supplier | purchase Tanespimycin (17-AAG) | Tanespimycin (17-AAG) cost | Tanespimycin (17-AAG) manufacturer | order Tanespimycin (17-AAG) | Tanespimycin (17-AAG) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID